VRDNViridian Therapeutics, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72,000+0.0% YoY

Gross Profit

$72,000100.0% margin

Operating Income

-$72M-100259.7% margin

Net Income

-$65M-90268.1% margin

EPS (Diluted)

$-1.02

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$46M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$586M

Total Liabilities

$56M

Stockholders' Equity

$529M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72,000	$72,000	+0.0%
Gross Profit	$72,000	$72,000	+0.0%
Operating Income	-$72M	-$59M	-21.8%
Net Income	-$65M	-$55M	-18.0%

Revenue Segments

Collaboration Revenue

$100,000100%

VRDN Q2 2024 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena